Clearside Biomedical, Inc. (CLSD), Wednesday said its ODYSSEY Phase 2b study of CLS-AX for the treatment of neovascular age-related macular degeneration (wet AMD) achieved primary goal. The company's shares were trading up more than 25 percent in pre-market activity.
In the ODYSSEY Phase 2b study, participants with wet AMD were randomized to receive either CLS-AX or standard of care therapy, aflibercept. The study achieved its primary goal of maintaining stable best corrected visual acuity (BCVA) throughout the trial. In participants who received CLS-AX, BCVA and ocular anatomy (central subfield thickness) were stable up to 6 months compared to participants who received aflibercept. About 67 percent of participants who received CLS-AX did not require any additional treatment up to 6 months. The study also met its secondary goals.
Additionally, the drug was well tolerated and no ocular or treatment-related serious adverse events were reported.
A Phase 3 study of CLS-AX in wet AMD is underway.
Clearside Biomedical stock had closed at $1.48, down 6.33 percent on Tuesday. It has traded in the range of $0.6500 - $2.1200 in the last 1 year.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.